Craig Hersh, MD
Pulmonary Disease · Boston, MANPI 1548214174
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $53,427 of the $56,773 with a category attached, or 94.1%. 5 manufacturers reported payments, led by Sanofi at 43.4% of the total. 2025 is the largest year on record at $24,679, more than ten times the $1,600 reported in 2020. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $1290.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$25K
- AstraZeneca$12K
- Genentech USA, Inc.$10K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- Chiesi USA, Inc.$5K
Across 48 payments — averaging $2576.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$51K
- Vertex$37K
- Boehringer Ingelheim$33K
- Boehringer Ingelheim Pharma GmbH & Co.kg$3K
What the payments were for
- Consulting fees$53,42794%
- Travel & lodging$1,6463%
- Food & beverage$1,7013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $24,640 |
| AstraZeneca | 15 | $11,626 |
| Genentech USA, Inc. | 11 | $9,916 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $6,041 |
| Chiesi USA, Inc. | 2 | $4,550 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,773 in reported general payments places this provider in the 90th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 39 | $359,096 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 174 | $136,434 |
| NucalaMepolizumab | 25 | $97,321 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 108 | $77,021 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 107 | $61,338 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $27,038 |
| Incruse ElliptaUmeclidinium Bromide | 58 | $24,051 |
| Advair HfaFluticasone Propion/Salmeterol | 34 | $10,630 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 23 | $10,593 |
| Tiotropium Bromide | 12 | $6,925 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $6,894 |
| DuleraMometasone/Formoterol | 15 | $5,955 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 154 | $5,820 |
| Wixela InhubFluticasone Propion/Salmeterol | 55 | $5,052 |
| Arnuity ElliptaFluticasone Furoate | 14 | $4,856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $11,626 | $94,509157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.